文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

卵巢癌中循环肿瘤细胞的检测及循环肿瘤细胞上皮-间质转化模式的评估

Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.

作者信息

Jie Xiao-Xiang, Zhang Meng, Du Ming, Cai Qing-Qing, Cong Qing, Xu Cong-Jian, Zhang Xiao-Yan

机构信息

Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, China.

出版信息

Transl Cancer Res. 2022 Aug;11(8):2636-2646. doi: 10.21037/tcr-22-529.


DOI:10.21037/tcr-22-529
PMID:36093536
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9459537/
Abstract

BACKGROUND: Circulating tumor cells (CTCs) have considered to be promising liquid biopsy in cancer due to the intact information of whole cells and the potential to reflect micrometastasis. However, CTCs research are extremely limited in ovarian cancer, probably due to their rarity. The predictive value of CTCs and circulating tumor microemboli (CTM) in metastasis remains to be elucidated in ovarian cancer. This study tried to identify CTCs/CTM in ovarian cancer with considerably positive rate. To preliminarily identify the invasive capacity of CTCs/CTM, the epithelial-mesenchymal transition (EMT) patterns of CTCs/CTM was evaluated. Moreover, for comprehensive understanding of invasiveness of disseminated cells in ovarian cancer, EMT pattern of exfoliated tumor cells in ascites were also confirmed in this study. METHODS: Peripheral blood samples and ascites samples were collected from 22 ovarian cancer patients. The Microfiltration combined with morphological analysis was used to detect CTC single cells or cell clusters. Microfiltration combined with morphological analysis was applied in the CTC isolation and identification. EMT was evaluated by immunofluorescence via markers including vimentin and cytokeratin. RESULTS: Microfiltration combined with morphological analysis was introduced to detect CTCs/CTM with a positivity rate of 40.9% in ovarian cancer patients. The number of CTC varied from 1 to 8, with CTM number from 4 to 30. CTCs/CTM of all samples have experienced EMT process. Vimentin was expressed in all CTC samples and all tumor cells in ascites, while cytokeratin was expressed in 44.4% (4/9) of CTC samples. There were no significant differences of the clinical parameters between the CTC-positive and CTC-negative patients. CONCLUSIONS: This study showed that both CTCs/CTM and detached tumor cells in ascites might have undergone complete or partial EMT in ovarian cancer. Moreover, microfiltration combined with cytomorphological analysis showed a considerable CTC detection rate.

摘要

背景:循环肿瘤细胞(CTCs)因其完整的全细胞信息以及反映微转移的潜力,被认为是癌症中很有前景的液体活检方法。然而,CTCs在卵巢癌中的研究极为有限,可能是由于其稀有性。CTCs和循环肿瘤微栓子(CTM)在卵巢癌转移中的预测价值仍有待阐明。本研究试图在卵巢癌中以相当高的阳性率识别CTCs/CTM。为初步鉴定CTCs/CTM的侵袭能力,评估了CTCs/CTM的上皮-间质转化(EMT)模式。此外,为全面了解卵巢癌中播散细胞的侵袭性,本研究还证实了腹水中脱落肿瘤细胞的EMT模式。 方法:收集22例卵巢癌患者的外周血样本和腹水样本。采用微滤结合形态学分析检测CTCs单细胞或细胞团簇。微滤结合形态学分析应用于CTCs的分离和鉴定。通过免疫荧光法,利用波形蛋白和细胞角蛋白等标志物评估EMT。 结果:引入微滤结合形态学分析检测卵巢癌患者的CTCs/CTM,阳性率为40.9%。CTCs数量从1到8不等,CTM数量从4到30不等。所有样本的CTCs/CTM都经历了EMT过程。波形蛋白在所有CTCs样本和腹水中的所有肿瘤细胞中均有表达,而细胞角蛋白在44.4%(4/9)的CTCs样本中有表达。CTCs阳性和阴性患者的临床参数无显著差异。 结论:本研究表明,卵巢癌中的CTCs/CTM和腹水中的脱落肿瘤细胞可能都经历了完全或部分EMT。此外,微滤结合细胞形态学分析显示CTCs检测率相当可观。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/3d3792d369e7/tcr-11-08-2636-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/6f0fae3c3852/tcr-11-08-2636-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/c7c3371bb46a/tcr-11-08-2636-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/3d3792d369e7/tcr-11-08-2636-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/6f0fae3c3852/tcr-11-08-2636-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/c7c3371bb46a/tcr-11-08-2636-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1845/9459537/3d3792d369e7/tcr-11-08-2636-f3.jpg

相似文献

[1]
Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.

Transl Cancer Res. 2022-8

[2]
Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.

Cancer Cell Int. 2017-1-5

[3]
Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.

Transl Oncol. 2017-6

[4]
Classification of circulating tumor cells by epithelial-mesenchymal transition markers.

PLoS One. 2015-4-24

[5]
Circulating tumor cells as a window on metastasis biology in lung cancer.

Am J Pathol. 2011-3

[6]
Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.

World J Gastroenterol. 2019-1-7

[7]
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

J Clin Oncol. 2012-1-17

[8]
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.

Cancer Commun (Lond). 2019-1-3

[9]
Circulating tumor microemboli: Progress in molecular understanding and enrichment technologies.

Biotechnol Adv. 2018-5-18

[10]
The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.

Oncologist. 2019-3-7

引用本文的文献

[1]
From Defense to Disease: How the Immune System Fuels Epithelial-Mesenchymal Transition in Ovarian Cancer.

Int J Mol Sci. 2025-4-24

[2]
EFHD1 Activates SIK3 to Limit Colorectal Cancer Initiation and Progression via the Hippo Pathway.

J Cancer. 2025-1-20

[3]
Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.

J Pharm Anal. 2023-12

[4]
Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.

Front Oncol. 2023-12-19

[5]
Single-cell analysis technologies for cancer research: from tumor-specific single cell discovery to cancer therapy.

Front Genet. 2023-10-12

本文引用的文献

[1]
Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition.

Sci Rep. 2021-3-22

[2]
Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.

Gynecol Oncol. 2021-5

[3]
Cancer Statistics, 2021.

CA Cancer J Clin. 2021-1

[4]
Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer.

Med Sci Monit. 2021-1-7

[5]
Photoacoustic Flow System for the Detection of Ovarian Circulating Tumor Cells Utilizing Copper Sulfide Nanoparticles.

ACS Biomater Sci Eng. 2019-3-11

[6]
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.

J Natl Cancer Inst. 2021-4-6

[7]
Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities.

Cancers (Basel). 2020-7-17

[8]
Significance of E-cadherin and Vimentin as epithelial-mesenchymal transition markers in colorectal carcinoma prognosis.

EXCLI J. 2020-6-26

[9]
Epithelial-Mesenchymal Transition Status of Circulating Tumor Cells Is Associated With Tumor Relapse in Head and Neck Squamous Cell Carcinoma.

Anticancer Res. 2020-6

[10]
Liquid biopsy in ovarian cancer.

Adv Clin Chem. 2020

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索